Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling

Marine Fidelle; Isabelle Lebhar; Laurence Zitvogel; Guido Kroemer

doi:10.1080/2162402X.2023.2224679

Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling

Marine Fidelle, Isabelle Lebhar, Laurence Zitvogel, Guido Kroemer

Résultats de recherche: Contribution à un journal › Editorial

2 Citations (Scopus)

Résumé

In a recent paper in Nature, Park et al. propose a mechanism through which intestinal dysbiosis compromises the efficacy of immunotherapy targeting the PD-L1/PD−1 interaction. Dysbiosis may upregulate a pair of checkpoint molecules, i.e. PD-L2 interacting with RGMb. Antibodies targeting PD-L2/RGMb can restore responses to PD−1 blockade in the context of dysbiosis.

langue originale	Anglais
Numéro d'article	2224679
journal	OncoImmunology
Volume	12
Numéro de publication	1
Les DOIs	https://doi.org/10.1080/2162402X.2023.2224679
état	Publié - 1 janv. 2023

Accès au document

10.1080/2162402X.2023.2224679

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{59920ea5f5f34b66b1137a240fac839e,

title = "Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling",

abstract = "In a recent paper in Nature, Park et al. propose a mechanism through which intestinal dysbiosis compromises the efficacy of immunotherapy targeting the PD-L1/PD−1 interaction. Dysbiosis may upregulate a pair of checkpoint molecules, i.e. PD-L2 interacting with RGMb. Antibodies targeting PD-L2/RGMb can restore responses to PD−1 blockade in the context of dysbiosis.",

author = "Marine Fidelle and Isabelle Lebhar and Laurence Zitvogel and Guido Kroemer",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2023",

month = jan,

day = "1",

doi = "10.1080/2162402X.2023.2224679",

language = "English",

volume = "12",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling

AU - Fidelle, Marine

AU - Lebhar, Isabelle

AU - Zitvogel, Laurence

AU - Kroemer, Guido

PY - 2023/1/1

Y1 - 2023/1/1

N2 - In a recent paper in Nature, Park et al. propose a mechanism through which intestinal dysbiosis compromises the efficacy of immunotherapy targeting the PD-L1/PD−1 interaction. Dysbiosis may upregulate a pair of checkpoint molecules, i.e. PD-L2 interacting with RGMb. Antibodies targeting PD-L2/RGMb can restore responses to PD−1 blockade in the context of dysbiosis.

AB - In a recent paper in Nature, Park et al. propose a mechanism through which intestinal dysbiosis compromises the efficacy of immunotherapy targeting the PD-L1/PD−1 interaction. Dysbiosis may upregulate a pair of checkpoint molecules, i.e. PD-L2 interacting with RGMb. Antibodies targeting PD-L2/RGMb can restore responses to PD−1 blockade in the context of dysbiosis.

UR - http://www.scopus.com/inward/record.url?scp=85163807102&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2023.2224679

DO - 10.1080/2162402X.2023.2224679

M3 - Editorial

C2 - 37396957

AN - SCOPUS:85163807102

SN - 2162-4011

VL - 12

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 2224679

ER -